Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.83 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.59 |
| ▸ | CCNK | O75909 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CCND3 | P30281 | 1/20 | 0.59 |
| ▸ | CDK9 | P50750 | 1/20 | 0.59 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.59 |
| ▸ | JAK3 | P52333 | 2/20 | 0.57 |
| ▸ | BTK | Q06187 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17059685 | 0.91 | EGFR (1.00) | EGFRJAK3BTK | |
| SCHEMBL17059592 | 0.90 | EGFR (0.84) | EGFRJAK3BTK | |
| SCHEMBL17059644 | 0.85 | EGFR (1.00) | EGFRJAK3BTK | |
| SCHEMBL10127802 | 0.84 | EGFR (0.87) | EGFRJAK3BTK | |
| SCHEMBL17059604 | 0.82 | EGFR (0.85) | EGFRJAK3BTK | |
| SCHEMBL17059694 | 0.81 | EGFR (1.00) | EGFRJAK3BTK | |
| SCHEMBL17059632 | 0.81 | EGFR (0.75) | EGFR | |
| SCHEMBL29847775 | 0.80 | FGFR1 (0.77) | EGFRCCNT1CCNKCYP3A4CCND3 | |
| SCHEMBL16515007 | 0.80 | FGFR1 (0.77) | EGFRCCNT1CCNKCYP3A4CCND3 | |
| SCHEMBL17059606 | 0.79 | EGFR (1.00) | EGFRJAK3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015127873-A1 | ARYLAMINO PYRAMIDINE COMPOUND AND APPLICATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS PREPARED THEREFROM | 上海海雁医药科技有限公司 | 2015-09-03 | — | — | WO | disclosed |